Be sure to check our sister interview main ratings news website

Why cold and flu season could be worse this year

Last year, we were spared a strong wave of colds and flu – the numbers were far below the level of previous years1. And that’s no wonder: due to COVID-19 and the protective measures taken, we have given cold and flu viruses hardly any chance to multiply. Thanks to vaccinations, restrictions are slowly being relaxed again in many countries. What does this mean for the upcoming cold and flu season and how can we strengthen our immune system? 

Bayer talked about this with Dr. Kizito Kyeremateng, Doctor of Pharmacy and Associate Medical Director at Bayer in the Consumer Health division. 

Poolbeg Pharma plc (LON:POLB) is a clinical stage infectious disease pharmaceutical company, with a novel capital light clinical model which enables us to develop multiple products faster and more cost effectively than the traditional biotech model. 

Read in Full
Click to view all articles for the EPIC:
Or click to view the full company profile:
Facebook
X
LinkedIn
Poolbeg Pharma

More articles like this

AI-powered drug discovery is changing the future of medicine

31st January 2025

The pharmaceutical industry is being revolutionised by AI, transforming drug discovery with faster research and innovative treatments. Poolbeg Pharma plc (LON:POLB) is a clinical stage infectious disease pharmaceutical company, leveraging a novel clinical model for faster product development.

The Medicine of Tomorrow

23rd January 2025

Discover how groundbreaking research is revolutionising disease treatment at Monash Institute of Pharmaceutical Sciences. AI, biology, and data converge for life-changing advancements.

Hookipa Pharma advancing bold acquisition plans with Poolbeg Pharma

9th January 2025

US-based biopharmaceutical innovator Hookipa Pharma is advancing non-binding discussions to acquire London-based Poolbeg Pharma in an all-share deal. This transformative proposal could reshape the clinical-stage biopharmaceutical landscape, creating a Nasdaq-listed powerhouse focused on next-generation immunotherapies for

Poolbeg receives US patent for Immunomodulator development

21st November 2024

Poolbeg Pharma plc, a clinical-stage biopharmaceutical company, has announced that the US Patent Office will grant its US Immunomodulator I patent application. The patent covers POLB 001, a selective p38 MAP kinase inhibitor, and other similar

Poolbeg Pharma awarded POLB 001 patent in United States

20th November 2024

Poolbeg Pharma plc (LON:POLB), a clinical-stage biopharmaceutical company focused on the development and commercialisation of innovative medicines targeting diseases with a high unmet medical need, has announced that the US Patent Office has notified the Company of its official decision

AI in Pharmaceuticals

14th November 2024

Artificial intelligence in the pharmaceutical industry has become central to modern drug discovery and development. Recognising both its potential and its risks, the FDA has initiated efforts to regulate AI’s role in the sector, balancing innovation

© 2024 – DirectorsTalk. All rights reserved. Reproduction in whole or in part, in any form or medium without express written permission is prohibited.